Menu
Fechar
hrs4r
 I want to donate
Firma
RUT PORTA-BALANYÀ
Position
Investigador/a Post-doctoral – R2
Postdoctoral Researchers – R2
Publicacions

Publicacions

Polonio-Alcalá E, Porta R, Ruiz-Martínez S, Vásquez-Dongo C, Relat J, Bosch-Barrera J, Ciurana J, Puig T

AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models.

BIOMEDICINE & PHARMACOTHERAPY, 2022, 156, 113942-113942 dx.doi.org/10.1016/j.biopha.2022.113942
Polonio-Alcalá E, Rabionet M, Ruiz-Martínez S, Palomeras S, Porta R, Vásquez-Dongo C, Bosch-Barrera J, Puig T, Ciurana J

Polycaprolactone Electrospun Scaffolds Produce an Enrichment of Lung Cancer Stem Cells in Sensitive and Resistant EGFRm Lung Adenocarcinoma

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13215320
Fort-Culillas R, Barahona San Millán R, Garcia-Fructuoso I, Quera González A, Grau Martín A, Puigdemont Guinart M, Rubió-Casadevall J, Recasens Sala M, Porta Balanyà R

Doege-Potter syndrome in a facial solitary fibrous tumor: Diagnose and clinical management discussion

Clinical Case Reports, 2021, 9 dx.doi.org/10.1002/ccr3.4291
Remon J, Nadal E, Dómine M, Ruffinelli J, García Y, Pardo JC, López R, Cilleruelo A, García-Campelo R, Martín P, Juan O, González-Larriba JL, Provencio M, Olmedo E, Ponce S, Cumplido D, Barenys C, Majem M, Massutti B, Rodriguez-Abreu D, Porta R, Sala MA, Martinez-Kareaga M, Lianes P, Reguart N

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

LUNG CANCER, 2020, 147, 83-90 dx.doi.org/10.1016/j.lungcan.2020.06.034
Carmona-Bayonas A, Gómez D, Martínez de Castro E, Pérez Segura P, Muñoz Langa J, Jimenez-Fonseca P, Sánchez Cánovas M, Ortega Moran L, García Escobar I, Rupérez Blanco AB, Fernández Pérez I, Martínez de Prado P, Porta I Balanyà R, Quintanar Verduguez T, Rodríguez-Lescure Á, Muñoz A

A snapshot of cancer-associated thromboembolic disease in 2018-2019: First data from the TESEO prospective registry

EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 78, 41-49 dx.doi.org/10.1016/j.ejim.2020.05.031
Santaballa A, Pinto Á, Balanyà RP, Ramírez Merino N, Martín IR, Grau SS, Fombella JPB, Cano JM, González CH, Bayo J

SEOM clinical guideline for secondary prevention (2019)

CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22, 187-192 dx.doi.org/10.1007/s12094-020-02302-0
Porta R, Borea R, Coelho A, Khan S, Araújo A, Reclusa P, Franchina T, Van Der Steen N, Van Dam P, Ferri J, Sirera R, Naing A, Hong D, Rolfo C

FGFR a promising druggable target in cancer: Molecular biology and new drugs.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 113, 256-267 dx.doi.org/10.1016/j.critrevonc.2017.02.018
Bosch-Barrera J, Sais E, Lorencio C, Porta R, Izquierdo A, Menéndez JA, Brunet J, Sirvent JM, Rosell R

Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma.

LUNG CANCER, 2014, 86, 102-104 dx.doi.org/10.1016/j.lungcan.2014.07.010
Porta R, Blancafort A, Casòliva G, Casas M, Dorca J, Buxo M, Viñas G, Oliveras G, Puig T

Fatty acid synthase expression is strongly related to menopause in early-stage breast cancer patients.

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2014, 21, 188-191 dx.doi.org/10.1097/GME.0b013e31829d17dc
Puig T, Vázquez-Martín A, Relat J, Pétriz J, Menéndez JA, Porta R, Casals G, Marrero PF, Haro D, Brunet J, Colomer R

Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75.

BREAST CANCER RESEARCH AND TREATMENT, 2008, 109, 471-479 dx.doi.org/10.1007/s10549-007-9678-5

Formulari de contacte

About IDIBGI!

 menu